Terminated PHASE2 INTERVENTIONAL 6-arm NCT04764448

A Study of Belcesiran in Patients With AATLD (ESTRELLA)

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Conditions Alpha 1-Antitrypsin Deficiency

Interventions Belcesiran Placebo

Updated 15 times since 2021 Last updated: Dec 6, 2024 Started: Feb 12, 2021 Primary completion: Dec 8, 2023 Completion: May 29, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Development project was discontinued

Other terminated trials from Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

See all terminations from Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Other Alpha 1-Antitrypsin Deficiency trials with similar outcome

Browse all Alpha 1-Antitrypsin Deficiency trials

A PHASE2 clinical study on Alpha 1-Antitrypsin Deficiency, this trial is terminated or withdrawn. The trial is conducted by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company and has accumulated 15 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

15 versions recorded

Feb 2025 — Present [monthly]

Terminated PHASE2
Dec 2024 — Feb 2025 [monthly]

Terminated PHASE2
Oct 2024 — Dec 2024 [monthly]

Terminated PHASE2
Sep 2024 — Oct 2024 [monthly]

Terminated PHASE2
Aug 2024 — Sep 2024 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated

▶ Show 10 earlier versions

Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
May 2023 — Apr 2024 [monthly]

Recruiting PHASE2
Feb 2023 — May 2023 [monthly]

Recruiting PHASE2
Dec 2022 — Feb 2023 [monthly]

Recruiting PHASE2
Sep 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Jan 2022 — Jul 2022 [monthly]

Recruiting PHASE2
Nov 2021 — Jan 2022 [monthly]

Recruiting PHASE2
Mar 2021 — Nov 2021 [monthly]

Recruiting PHASE2

First recorded

Feb 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Cambridge, United Kingdom , Charleston, United States , Creixomil, Portugal , Dublin, Ireland , Gainesville, United States , Grafton, New Zealand , Hamilton, New Zealand , Innsbruck, Austria , Kiel, Germany and 13 more locations